2,4-Dimethyl-benzylmethylether | 54617-15-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,4-Dimethyl-benzylmethylether
• 英文别名: 2,5-Dimethylbenzylmethylether；2-(Methoxymethyl)-1,4-dimethylbenzene
• CAS: 54617-15-1
• 化学式: C₁₀H₁₄O
• 分子量: 150.221
• InChiKey: HJXDVXRAWHDORF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2,4-Dimethyl-benzylmethylether 、 乙腈 在 三氯化铁 作用下， 反应 36.0h， 以98%的产率得到N-(2,5-dimethylbenzyl)acetamide
  参考文献：
  名称：

  通过氯化苄或苄基甲基醚与乙腈的路易斯酸催化反应制备 N-苄基乙酰胺的简单、高产率

  摘要：

  摘要 苄基氯或苄基甲基醚与水合氯化铁在乙腈中的反应会导致平稳的 Ritter 反应并以优异的产率形成 N-苄基乙酰胺。

  DOI：

  10.1080/00397919308018613

文献信息

• 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor
  申请人：Mizojiri Ryo

  公开号：US20090036444A1

  公开（公告）日：2009-02-05

  The present invention relates to a fused ring compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种由以下式[I]表示的融合环化合物，其中每个符号如规范中所定义，或其药学上可接受的盐，以及一种丙型肝炎病毒（HCV）聚合酶抑制剂和治疗丙型肝炎的药物，本发明的化合物基于HCV聚合酶抑制活性具有抗HCV活性，是一种预防或治疗丙型肝炎的药剂。
• Fused-ring compounds and use thereof as drugs
  申请人：Hashimoto Hiromasa

  公开号：US20070032497A1

  公开（公告）日：2007-02-08

  The present invention provides a fused ring compound of the following formula [I] wherein each symbol is as defined in the specification, a pharmaceutically acceptable salt thereof, and a therapeutic agent for hepatitis C, which contains this compound. The compound of the present invention shows an anti-hapatitis C virus (HCV) action based on the HCV polymerase inhibitory activity, and is useful as a therapeutic agent or prophylactic agent for hepatitis C.

  本发明提供了以下式[I]的融合环化合物，其中每个符号如规范中定义的，其药学上可接受的盐以及包含该化合物的丙型肝炎治疗剂。本发明的化合物显示出基于丙型肝炎病毒（HCV）聚合酶抑制活性的抗HCV作用，并且可用作丙型肝炎的治疗剂或预防剂。
• Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
  申请人：Oka Takahiro

  公开号：US20070049593A1

  公开（公告）日：2007-03-01

  The present invention relates to a tetracyclic fused heterocyclic compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种四环融合杂环化合物，其化学式为[I]，其中每个符号的定义如规范中所述，或其药学上可接受的盐，以及一种丙型肝炎病毒（HCV）聚合酶抑制剂和治疗丙型肝炎的药物，本发明的化合物表现出基于HCV聚合酶抑制活性的抗HCV活性，因此可用作预防或治疗丙型肝炎的药物。
• TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR
  申请人：Oka Takahiro

  公开号：US20120070409A1

  公开（公告）日：2012-03-22

  The present invention relates to a tetracyclic fused heterocyclic compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种四环融合杂环化合物，其表示为以下公式[I]，其中每个符号如规范中所定义，或其药学上可接受的盐，以及一种丙型肝炎病毒（HCV）聚合酶抑制剂和治疗丙型肝炎的药物，本发明的化合物基于HCV聚合酶抑制活性显示出抗HCV活性，可用作预防或治疗丙型肝炎的药物。
• 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR
  申请人：Mizojiri Ryo

  公开号：US20120020920A1

  公开（公告）日：2012-01-26

  The present invention relates to a fused ring compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种由以下式[I]所表示的融合环化合物，其中每个符号如规范中所定义，或其药学上可接受的盐，以及一种丙型肝炎病毒（HCV）聚合酶抑制剂和治疗丙型肝炎的药物，本发明化合物基于HCV聚合酶抑制活性具有抗HCV活性，可用作预防或治疗丙型肝炎的药剂。